T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals
Open accessPublished version of a preprint
Abstract
(Cell 185, 1041–1051.e1–e6; March 17, 2022) In our originally published article, an error in production resulted in mistakes to the citations and references for Garcia-Beltran et al., 2021a, 2021b, and 2022. At publication, Garcia-Beltran et al., 2021a referred to the Correction for the original Garcia-Beltran et al., 2021a, which ran in Cell volume 184 on page 2532; instead, it should refer to the original article, which ran in Cell volume 184 on pages 2372–2383.e9. Garcia-Beltran et al., 2021b referred to the BioRxiv pre-print publication of Garcia-Beltran et al., 2022; instead, it should refer to Garcia-Beltran et al., 2021, Cell 184, 476–488.e11. The references have now been corrected online. To coincide with corrections to the references, the citations in the following sentences have also been corrected as indicated: • “Additional booster vaccine doses partially compensate for this effect (Garcia-Beltran et al., 2021b; Hoffmann et al., 2021)” now refers to Garcia-Beltran et al. (2022). • “Within this cohort of individuals, we recently reported markedly reduced neutralization of Omicron following primary series vaccination, which was overcome by additional ‘booster’ doses (Garcia-Beltran et al., 2021b)” now refers to Garcia-Beltran et al. (2022). • “Using a pseudoneutralization titer threshold of 20 (Garcia-Beltran et al., 2022)” now refers to Garcia-Beltran et al. (2021b). • In Figure 4D, “Dotted lines denote a pseudoneutralization titer threshold of 20 (Garcia-Beltran et al., 2021c)” now refers to Garcia-Beltran et al. (2021b). • “The SARS-CoV-2 Omicron variant demonstrates substantial escape from neutralizing antibody responses (Garcia-Beltran et al., 2021b; Hoffmann et al., 2021)” now refers to Garcia-Beltran et al. (2022). The journal apologizes for any confusion these errors may have caused. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individualsNaranbhai et al.CellFebruary 2, 2022In BriefT cells from most SARS-CoV-2 infected and/or vaccinated individuals have preserved reactivity to the Omicron variant, and their reactivity is enhanced by booster vaccination. However, ∼20% of individuals have reduced T cell recognition of the Omicron spike, potentially due to escape of HLA class I-restricted epitopes. Full-Text PDF Open Access
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A subset of individuals (approximately 21%) exhibited a more than 50% decrease in T cell reactivity to the Omicron spike.
“However, a subset of individuals (approximately 21%) exhibited a more than 50% decrease in T cell reactivity to the Omicron spike28.”
From An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial (2024) · cites this paper as [28]
Naranbhai et al. showed that T cell cross-reactivity to the SARS-CoV-2 Omicron variant remained intact in most of the previously infected and vaccinated individuals.
“A study published by Naranbhai et al.28 showed that T cell cross-reactivity to the SARS-CoV-2 Omicron variant remained intact in most of the previously infected and vaccinated individuals.”
From An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial (2024) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19
Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Cheng, L., Li, J., Wang, X., Wang, F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0901-9 · Cited by 2,614 · see citing works
Rydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S., Abbott, R. K., Kim, C., Choi, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.038 · Cited by 1,790 · see citing works
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788 · see citing works
Peng, Y., Mentzer, A. J., Liu, G., Yao, X., Yin, Z., Dong, D., Dejnirattisai, W., Rostron, T., Supasa, P., Liu, C., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0782-6 · Cited by 1,179 · see citing works
Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques
McMahan, K., Yu, J., Mercado, N. B., Loos, C., Tostanoski, L. H., Chandrashekar, A., Liu, J., Peter, L., Atyeo, C., Zhu, A., et al. (2021) · Nature · doi:10.1038/s41586-020-03041-6 · Cited by 1,068 · see citing works
Migueles, S. A., Laborico, A. C., Shupert, W. L., Sabbaghian, M. S., Rabin, R. L., Hallahan, C. W., van Baarle, D., Kostense, S., Miedema, F. F., McLaughlin, M. E., et al. (2002) · Nature Immunology · doi:10.1038/ni845 · Cited by 1,004 · see citing works
Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.032 · Cited by 889 · see citing works
Advances in Fmoc solid‐phase peptide synthesis
Behrendt, R., White, P., & Offer, J. (2016) · Journal of Peptide Science · doi:10.1002/psc.2836 · Cited by 767 · see citing works
Tan, A. T., Linster, M., Tan, C. W., Le Bert, N., Chia, W. N., Kunasegaran, K., Zhuang, Y., Tham, C. Y. L., Chia, A., Smith, G. J. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108728 · Cited by 740 · see citing works
COVID-19 Neutralizing Antibodies Predict Disease Severity and Survival
García-Beltrán, W. F., Lam, E. C., Astudillo, M. G., Yang, D., Miller, T. E., Feldman, J. E., Hauser, B. M., Caradonna, T. M., Clayton, K., Nitido, A. D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.12.015 · Cited by 701 · see citing works
Self-citationVanBlargan, L. A., Errico, J. M., Halfmann, P., Zost, S. J., Crowe, J. E., Purcell, L. A., Kawaoka, Y., Corti, D., Fremont, D. H., & Diamond, M. (2022) · Nature Medicine · doi:10.1038/s41591-021-01678-y · Cited by 676 · see citing works
Migueles, S. A., Osborne, C. M., Royce, C., Compton, A. A., Joshi, R. P., Weeks, K. A., Rood, J. E., Berkley, A. M., Sacha, J. B., Cogliano-Shutta, N. A., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.10.010 · Cited by 586 · see citing works
Geers, D., Shamier, M. C., Bogers, S., den Hartog, G., Gommers, L., Nieuwkoop, N. N., Schmitz, K. S., Rijsbergen, L. C., van Osch, J. A. T., Dijkhuizen, E., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abj1750 · Cited by 529 · see citing works
Painter, M. M., Mathew, D., Goel, R. R., Apostolidis, S. A., Pattekar, A., Kuthuru, O., Baxter, A. E., Herati, R. S., Oldridge, D. A., Gouma, S., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.001 · Cited by 499 · see citing works
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
García-Beltrán, W. F., Lam, E. C., Denis, K. S., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J. E., Pavlovic, M., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.04.006 · Cited by 446 · see citing works
Self-citationCHATZI, K. B. O., GATOS, D., & STAVROPOULOS, G. (1991) · International journal of peptide & protein research · doi:10.1111/j.1399-3011.1991.tb00769.x · Cited by 409 · see citing works
VanBlargan, L., Errico, J., Halfmann, P., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1175516/v1 · Cited by 293 · see citing works
Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19Preprint
Sekine, T., Perez‐Potti, A., Rivera‐Ballesteros, O., Strålin, K., Gorin, J., Olsson, A., Llewellyn‐Lacey, S., Kamal, H., Bogdanović, G., Muschiol, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.29.174888 · Cited by 272 · see citing works
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
Viana, R. P. E. S., Moyo, S. M., Amoako, D. G., Tegally, H., Scheepers, C., Althaus, C. L., Anyaneji, U. J., Bester, P. A., Boni, M. F., Chand, M., et al. (2022) · Nature · doi:10.1101/2021.12.19.21268028 · Cited by 250 · see citing works
An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain
Greaney, A. J., Starr, T. N., & Bloom, J. D. (2022) · Virus Evolution · doi:10.1093/ve/veac021 · Cited by 147 · see citing works
Naranbhai, V., García-Beltrán, W. F., Chang, C. C., Berrios, C., Thierauf, J., Kirkpatrick, G., Onozato, M. L., Cheng, J., Denis, K. S., Lam, E. C., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab593 · Cited by 135 · see citing works
Self-citationPeng, Y., Mentzer, A. J., Liu, G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.05.134551 · Cited by 96 · see citing works
Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses
Nathan, A., Rossin, E. J., Kaseke, C., Park, R. J.-H., Khatri, A., Koundakjian, D., Urbach, J. M., Singh, N. K., Bashirova, A. A., Tano-Menka, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.029 · Cited by 84 · see citing works
Self-citationNdhlovu, Z. M., Chibnik, L. B., Proudfoot, J., Vine, S. M., McMullen, A. M., Cesa, K. T., Porichis, F., Jones, R. B., Alvino, D. M. L., Hart, M. G., et al. (2012) · Blood · doi:10.1182/blood-2012-06-436295 · Cited by 73 · see citing works
Self-citationMeyers, L. M., Gutiérrez, A. H., Boyle, C., Terry, F. E., McGonnigal, B., Salazar, A. Μ., Princiotta, M. F., Martin, W. D., Groot, A. S. D., & Moise, L. (2021) · npj Vaccines · doi:10.1038/s41541-021-00331-6 · Cited by 43 · see citing works
mRNA-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-CoV-2 Omicron VariantPreprint
Garcia-Beltran, W. F., Denis, K. S., Hoelzemer, A., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3985605 · Cited by 37 · see citing works
Self-citationIkemura, N., Hoshino, A., Higuchi, Y., Taminishi, S., Inaba, T., & Matoba, S. (2021) · medRxiv · doi:10.1101/2021.12.13.21267761 · Cited by 34 · see citing works
The use of Dodt as a Non-Malodorous Scavenger in Fmoc-Based Peptide Synthesis
Teixeira, A., Benckhuijsen, W. E., de Koning, P. D., et al. (2002) · Protein and Peptide Letters · doi:10.2174/0929866023408481 · Cited by 33 · see citing works
Immunogenicity of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines
Naranbhai, V., Garcia-Beltran, W., Mairena, C. B., Thierauf, J., Chang, C. C., Kirkpatrick, G., Onozato, M., Cheng, J., Denis, K. J. S., Lam, E., et al. (2021) · medRxiv · doi:10.1101/2021.07.18.21260732 · Cited by 8 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: https://doi.org/10.1101/2022.01.04.21268586; this version posted January 5, 2022. The copyright holder for this preprint · DOI
Cited by
Sorted by citations
An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
Saraf, A., Gurjar, R., Kaviraj, S., Kulkarni, A., Kumar, D., Kulkarni, R., Virkar, R., Krishnan, J., Yadav, A., Baranwal, E., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02955-2 · Cited by 66 · see citing works
- Authors
- Naranbhai, V., Nathan, A., Kaseke, C., Berrios, C., Khatri, A., Choi, S., Getz, M. A., Tano-Menka, R., Ofoman, O., Gayton, A., Senjobe, F., Zhao, Z., St Denis, K. J., Lam, E. C., Carrington, M., Garcia-Beltran, W. F., Balazs, A. B., Walker, B. D., Iafrate, A. J., & Gaiha, G. D.
- Corresponding author
- Naranbhai, Vivek
- Gaiha, Gaurav D.
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 185
- Issue
- 7
- Pages
- 1259
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC8750712
- OpenAlex
- W4226089887
- Cited by
- 88
- References
- 29
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 13 · 2023: 16 · 2022: 49 · 2013: 1
- FWCI
- 10.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cell (publishedVersion, cc-by)
- medRxiv (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Bill and Melinda Gates Foundation
- Gilead Sciences
- Ragon Institute of MGH, MIT and Harvard
- Massachusetts Consortium on Pathogen Readiness
- National Institutes of Health (DK011794)
- National Institute on Drug Abuse (DP2DA040254)
- National Institute of General Medical Sciences (T32GM007753)
- National Institute of Allergy and Infectious Diseases (R01AI149704, UM1AI144462)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- T cell response, Omicron variant, COVID-19 pandemic, cross-reactivity, SARS-CoV-2 spike protein, neutralizing antibodies, antibody escape, booster vaccination, T cell memory, SARS-CoV-2 variants of concern, SARS-CoV
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
